Joint Replacement Infections: What You Need to Know
"A closer look at prosthetic joint infections, their causes, and preventative measures."
Joint replacement surgery has become a common and effective procedure for improving the quality of life for individuals suffering from chronic joint pain and mobility issues. While these surgeries generally have high success rates, prosthetic joint infections (PJIs) remain a serious complication that can lead to significant morbidity, prolonged hospital stays, and additional surgical interventions.
A recent study by Erik Lenguerrand and colleagues, published in The Lancet Infectious Diseases, highlighted important modifiable risk factors associated with PJIs following hip arthroplasty. Their work underscores the need for a comprehensive understanding of the factors contributing to these infections and the implementation of strategies to minimize their occurrence.
This article delves into the complexities surrounding prosthetic joint infections, drawing insights from the latest research and expert opinions to provide a clear and accessible overview of this critical issue. We will explore the incidence, risk factors, diagnosis, prevention, and management of PJIs, with the aim of empowering patients and healthcare professionals to make informed decisions and improve outcomes.
Incidence and Clinical Impact
A 2023 cohort study examined prosthetic joint infection (PJI) incidence, microbiology, and associated patient and surgical factors at three time points after total knee arthroplasty among US veterans. The supplied source information does not report the study’s incidence figures, so no rate can be stated here. A clinical review describes PJI as a serious complication of prosthetic joint implantation, including total hip and total knee arthroplasty.
A Long History of Joint Surgery
A historical overview notes that joint diseases have troubled people since ancient times. It credits generations of surgeons with introducing surgical techniques and advancing implant materials and designs. The overview also reports that prosthetic joint infections were a major reason for development in this field, though the provided snippet does not specify particular milestones or dates.
Understanding the Scope of Prosthetic Joint Infections
Prosthetic joint infections can occur at any time after joint replacement surgery, but they are broadly classified into early-onset and late-onset infections. Early-onset infections typically manifest within the first few months after surgery, while late-onset infections occur more than 24 months post-implantation. A study found that 42% of prosthetic joint infections were diagnosed as late-onset infections, highlighting the importance of long-term monitoring and vigilance.
- Early-Onset Infections: Typically occur within the first few months after surgery and are often caused by bacteria introduced during the surgical procedure.
- Late-Onset Infections: Occur more than 24 months post-implantation and may result from the spread of bacteria from other parts of the body or reactivation of dormant bacteria.
- Risk Factors: Factors that increase the risk of developing a prosthetic joint infection include obesity, diabetes, compromised immune system, and previous joint surgery.
Recent Reviews and Treatment Research
A review published August 14, 2025, describes PJI as a challenging complication in orthopedic surgery and reports incidence of 1%–2% for primary arthroplasties, with significantly higher rates for revision procedures. It also reports mortality rates of 8%–25% within five years. A separate source lists a June 2026 multicenter retrospective cohort examining predictors of treatment failure for hip and knee PJI treated with one- or two-stage exchange arthroplasty; the supplied material does not give its findings.
Limits in Prevention Evidence
A systematic review and meta-analysis of randomized controlled trials on antibiotics and antiseptics for preventing infection in people receiving primary total hip and knee prostheses identified limits in the evidence. It could not meta-analyze several endpoints because too few randomized trials examined them. The authors also said that, despite a comprehensive search, they could not be fully confident that all trials had been identified. Separately, research on implant surface technology and bacterial adhesion awaits validation in clinical studies.
Comparing Risk and Revision Approaches
In a study of 255,568 patients, Kao et al. reported no difference in PJI risk between total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients who had a dental procedure within two years after arthroplasty and those who did not. For chronic knee PJI, one- and two-stage revision are both described as main treatment options, but the best choice remains debated. A 2023 study concluded that 1.5-stage exchange appeared to be an acceptable alternative to two-stage exchange for hip PJI, with noninferior infection eradication.
Prevention is Key: Reducing Your Risk of Joint Infection
Preventing prosthetic joint infections requires a multifaceted approach involving meticulous surgical technique, appropriate antibiotic prophylaxis, and patient education. By understanding the risk factors and implementing evidence-based strategies, healthcare professionals and patients can work together to minimize the occurrence of these debilitating infections and ensure the long-term success of joint replacement surgery.
Care Requires Coordination
A 2023 review of current clinical challenges in PJI focuses on multidisciplinary collaboration alongside diagnosis and management. A separate narrative review, published December 2, 2025, synthesizes peer-reviewed clinical studies, consensus statements, and major international guidelines addressing PJI in hip, knee, and shoulder arthroplasty. Together, these sources frame PJI care as an area informed by both collaborative practice and a broad evidence base.
Research Trends and Projected Market Growth
A December 2024 bibliometric analysis investigates worldwide research trends, developing patterns, and main areas of focus in artificial joint infection research, with the stated aim of informing clinical practice and therapeutic techniques. Separately, a market analysis published July 15, 2026, projects steady growth in the prosthetic joint infections treatment market through 2034. It attributes that projection to expanding arthroplasty procedure volumes, new reimbursement pathways, and continued innovation in antibiotic delivery and implant surface technology; this is a market projection, not a clinical outcome.
The Burden of PJI
A review describes PJI as a major clinical challenge after total joint arthroplasty. It associates the infection with prolonged antimicrobial therapy, repeated surgery, implant failure, functional disability, and substantial socioeconomic burden. The same source lists systemic antibiotics, debridement with implant retention, staged revision, and antibiotic-loaded approaches among current strategies.